黑料网官网

Was found in 2016 to provide new solution for improving human health by transferring the novel technology platform developed in the CRI center for Chemical Proteomics at Seoul National University to the real drug discovery process. SPARK BIOPHARMA, Inc. envisions that the fundamental understanding of human disease in the molecular levels can help to create the new foundation for the generation of first-in-class small-molecule therapeutics through the integration of biology, chemistry, proteomics and informatics.